OncoZenge: Licensing agreement with Avernus Pharma - Redeye

Redeye comments on OncoZenge’s announcement of an exclusive licensing agreement with Avernus Pharma for the commercialization of BupiZenge in the Gulf Cooperation Council (GCC) region. Following the recently finalized European deal with Molteni Farmaceutici, we see this as another strategically important step in OncoZenge’s global commercialization strategy, broadening its geographic footprint and unlocking future potential in an underserved market for supportive oncology care.

Länk till analysen i sin helhet: https://www.redeye.se/research/1094684/oncozenge-licensing-agreement-with-avernus-pharma?utm_source=finwire&utm_medium=RSS